The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Here are the top 5 biosimilar articles for the week of June 23, 2025.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek

December 2nd 2024

By Skylar Jeremias

Article

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology conditions, including psoriatic arthritis and inflammatory bowel disease.

Perceptions of Biosimilar Switching Among Veterans With IBD

December 2nd 2024

By Deana Ferreri, PhD

Article

Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.

Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition

December 1st 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.

Biosimilars Gastroenterology Roundup: November 2024

November 30th 2024

By Skylar Jeremias

Article

In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms grew; Celltrion expanded its portfolio; and Global Biosimilars Week focused on improving affordability and equity.

The Top 5 Biosimilar Articles for the Week of November 25

November 29th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of November 25, 2024.

Biosimilar Approval and Uptake Impacted by Global Regulatory Frameworks

November 28th 2024

By Cameron Santoro

Article

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions.

Retrospective Study Shows Bevacizumab Biosimilar Efficacy in NSCLC

November 27th 2024

By Skylar Jeremias

Article

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in advanced non–small cell lung cancer (NSCLC)

Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy

November 27th 2024

By Skylar Jeremias

Article

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.

Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone

November 26th 2024

By Ashling Wahner

Article

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.

Ocrelizumab Biosimilar Shows Equivalent Efficacy as Multiple Sclerosis Treatment

November 26th 2024

By Skylar Jeremias

Article

The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and efficacy in treating relapsing multiple sclerosis over 96 weeks.